Once-daily directly observed therapy lopinavir/ritonavir plus indinavir as a protease inhibitor-only salvage therapy in heavily pretreated HIV-1-infected patients: A pilot study

AIDS

Volumn 20, Issue 1, 2006, Pages 129-131

  Elzi, Luigia ^a   Hirsch, Hans H ^a,b   Battegay, Manuel ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNE DEFICIENCY; LIVER TOXICITY; MALE; NEPHROTOXICITY; PATIENT; PILOT STUDY; PRIORITY JOURNAL; SALVAGE THERAPY; VIRUS INHIBITION;

EID: 29144524955     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000196174.80798.5b     Document Type: Article

References (13)

1. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:100-129.
2. Kappelhoff BS, Crommentuyn KML, De Maat MMR, Mulder JW, Huitema ADR, Beijnen JH. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet 2004; 43:845-853.
3. Lauenroth-Mai E, Gellermann H, Fenske S, Mondorf W. Multicenter study of an indinavir/lopinavir based regimen excluding NRTIs in salvage therapy of nucleoside-analogues experienced patients (MILESTONE). In: 7th International Congress on HIV Drug Therapy. Glasgow, UK, 2004 [Abstract P065].
4. Dauer B, Von Hentig N, Müller A, Carlebach A, Mösch M, Haberl A, et al. The CRIXILOP cohort study: preliminary results from a salvage study of the boosted double protease inhibitor (PI) regimen containing indinavir plus lopinavir/ritonavir without the addition of reverse transcriptase inhibitors in heavily therapy-experienced HIV patients. In: 9th European AIDS Conference (EACS). Warsaw, Poland, 2003 [Abstract 7.4/4].
5. Eron JJ, Feinberg J, Kessler HA, Horowitz HW, Witt MD, Carpio FF, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. Clin Infect Dis 2004; 189:265-272.
6. Ghosn J, Lamotte C, Ait-Mohand H, Wirden M, Agher R, Schneider L, et al. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS 2003; 17:209-214.
7. Von Hentig N, Dauer B, Moesch M, Carlebach A, Lutz T, Kurowski M, et al. Indinavir plasma exposure is not affected by ritonavir/lopinavir co-administration in a boosted double PI-only therapy regimen. In: 9th European AIDS Conference (EACS). Warsaw, Poland, 2003 [Abstract F2/4].
8. Tseng A, Phillips E, Antoniou T, Walker S, van Heeswijk R, Giguère P. Steady-state pharmacokinetics and tolerability of indinavir when coadministered with lopinavir/r in antiretroviral-experienced subjects. 4th International Workshop on Clinical Pharmacology of HIV therapy, Cannes 2003. abstract 8.10.
9. Isaac A, Taylor S, Cane P, Smit E, Gibbons SE, White DJ, et al. Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. J Antimicrob Chemother 2004; 54:498-502.
10. Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in HIV-infected patients. Antimicrobiol Agents Chemother 2003; 47:238-243.
11. min is associated with higher toxicity in patients on indinavir/ritonavir 800/100 mg twice-daily regimen. J Acquir Immune Defic Syndr 2002; 29:373-377.
12. Boffito M, Arnaudo I, Raiteri R, Bonora S, Sinicco A, Di Garbo A, et al. Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS 2002; 16:2081-2083.
13. Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis 2005; 40:174-181.